Backed by companies like Nvidia Corp. NVDA, Amazon.com Inc. AMZN, and Meta Platforms Inc. META, Scale AI is reportedly seeking a valuation of up to $25 billion in a new tender offer.
What Happened: Scale AI is in talks to launch a tender offer that could value the company at nearly double its previous valuation of $14 billion from last year, reported Business Insider, citing multiple sources who have seen the deal.
The terms of the deal, where existing shares are sold by early investors or employees, are still being finalized, and the final valuation could fluctuate, the report noted.
Founded in 2016, the San Francisco-based company plays a critical role in the AI ecosystem by providing high-quality labeled data, essential for training models like OpenAI's ChatGPT.
However, the company is also facing scrutiny. The U.S. Department of Labor is reportedly investigating Scale AI's compliance with the Fair Labor Standards Act, raising questions about labor practices amid its rapid growth.
Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox.
Why It's Important: On Friday, Elon Musk also acquired his social media platform X through xAI in a $33 billion deal.
Last month, it was reported that Ilya Sutskever, OpenAI’s co-founder and former chief scientist, is reportedly securing over $1 billion in funding for his AI startup, Safe Superintelligence (SSI), driving its valuation past $30 billion.
SoftBank Group SFTBF SFTBY is also reportedly in discussions to lead a new funding round for OpenAI, aiming to raise $40 billion. This investment could push the ChatGPT creator's valuation to $300 billion, marking a record for private company funding.
Check out more of Benzinga's Consumer Tech coverage by following this link.
Read Next:
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.